Plain-English translation of NCT05786443 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called empagliflozin to see if it can help protect kidney function and improve health in people who are starting hemodialysis due to end-stage kidney disease. Half of the participants will receive the medication daily, and the other half will receive a placebo (a pill with no active ingredient). The study will last 12 weeks and will track how safe the medication is and whether it helps prevent complications.
People on hemodialysis often lose what little remaining kidney function they have left, which can lead to serious health problems. Researchers want to see if this medication might help preserve that remaining function and improve outcomes for dialysis patients.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will take either the medication or a placebo pill once daily for 12 weeks while continuing your regular hemodialysis schedule. You will visit the research center for check-ups and blood tests to see how the medication is working and to monitor your health and kidney function. The study team will carefully track any side effects and how you are doing throughout the 12-week period.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
NYU Langone Health
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Boehringer Ingelheim
Enrollment target
~60 participants
Started
January 2024
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
David Charytan, MD, MSc
NYU Langone Health
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.